Member Info for cascudi

5cUS dollar is 4.5p is10pc yield .. very good

IN THE KNOW: Numis Welcomes Good Cash Performance From Acal Acal delivered a robust set of results and should trade at a narrower discount to peers, Numis said. On Tuesday, Acal which makes and..

https://www.youtube.com/watch?v=PmZOBdSu7sg

i was expecting more increase with such good trades.. there must be a big seller out there. as soon as he will be out.. share price should start to increase what is level 2 status?

good buy today

The Board is recommending an increase in the interim dividend of 5% to 2.45p per share (H1 2015/16: 2.33p per share). Since 2010, the full year dividend per share has risen by 58%

good volume also interim looks very good too nice cash flow

Nice raise

3 times higher 3 months average. Contract win. Good balance sheet. Interesting company

https://blogs.which.co.uk/technology/audio/electric-jukebox-can-this-new-streaming-service-beat-its-rivals/ It may seem expensive but compare two years of Electric Jukebox listening with two years of Spotify subscription and they both come to £240. After that Electric Jukebox works out at £60 cheaper each year. Subscriptions have their advantages of course – monthly chunks are more manageable than a yearly payout – but in the long term Electric Jukebox can save you money.

John21 mine was a question. I see good news at the moment and I guess the trend up is predicting a good future? PE to me are not important if the eps is growing

Back to 50p?

Start moving

Nice trend and nice volume

.

Waterman is in excellent shape, having reported results which exceed its previously declared financial objectives over the three year period to 30 June 2016 of tripling adjusted annual profit before tax to GBP3.3m, delivering GBP3.6m and increasing Return on Capital Employed to over 20%, delivering 47%

Sinclair Pharma plc Delivering strong growth, completed transformational US distribution deal, on track to meet full year guidance Sinclair Pharma plc (SPH.L), ("Sinclair", or the "Group", or the "Company") the international specialty pharma company, today announces its unaudited results for the six and twelve month periods ended 30 June 2016. Highlights - Reported revenues show significant growth reflecting strong in market sales and planned de-stocking in prior six month period. Group revenues increased 125% to GBP17.3 million compared to GBP7.7 million in the previous six month period o On track to meet guidance of 40% sales growth for calendar year 2016, pre Brazil consolidation and US Silhouette Soft(R) sales o Silhouette Soft(R) sales increased 94% to GBP6.2 million (GBP3.2 million for the previous six months) o Ellansé(R) sales increased 147% to GBP4.2 million (GBP1.7 million in the previous six months) o Perfectha(R) sales up 184% to GBP3.7 million (GBP1.3 million in the previous six months) o Sculptra(R) sales back on track, up 146% to GBP3.2 million (GBP1.5 million in the previous six months) o Distributor inventory levels remain normalised

Huge trade today

nice buy 14.75k

very undervalued in my opinion